

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Effect of Pamidronate on bone pains in patients with Malignancy

#### Protocol summary

##### Summary

**Purpose:** The purpose of this study was to examine the effect of Pamidronate on bone pains in Cancer patients.  
**Design:** This study was carried out on 41 patients with malignancy in Imam Sajad Hospital of Ramsar. Setting and conduct: This quasi-experimental study was carried out through convenience sampling method using a questionnaire and Visual Analog Scale (VAS). Inclusion criteria: Malignancy with bone metastasis Exclusion criteria: Renal dysfunction history or Creatinine more than 2mg/dl, Treatment of Hypocalcemia with other Bisphosphonates Intervention: In this study, Pamidronate (90 mg) was intravenously injected up to 3 months (one per month). Main outcome measures: Bone pains

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2013032212197N5**  
Registration date: **2013-05-05, 1392/02/15**  
Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2013-05-05, 1392/02/15

##### Registrant information

###### Name

Maryam Zakerihamidi

###### Name of organization / entity

Tonekabon Islamic Azad University

###### Country

Iran (Islamic Republic of)

###### Phone

+98 19 1224 5014

###### Email address

maryamzakerihamidi@yahoo.co.nz

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice chancellor for research of Tonekabon Islamic Azad University

##### Expected recruitment start date

2010-02-04, 1388/11/15

##### Expected recruitment end date

2011-02-04, 1389/11/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Effect of Pamidronate on bone pains in patients with Malignancy

##### Public title

Effect of Pamidronate on treatment of bone pains

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria: Malignancy with bone metastasis  
Exclusion criteria: Renal dysfunction history, Creatinine more than 2mg/dl, Treatment of Hypocalcemia with other Bisphosphonates

##### Age

No age limit

##### Gender

Both

##### Phase

2

##### Groups that have been masked

*No information*

##### Sample size

Target sample size: **41**

##### Randomization (investigator's opinion)

N/A

## Randomization description

### Blinding (investigator's opinion)

Not blinded

### Blinding description

#### Placebo

Not used

#### Assignment

Single

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Tonekabon Islamic Azad University

##### Street address

Islamic Azad University, Tonekabon, Vali Abad, Mazandaran, Iran

##### City

Tonekabon

##### Postal code

#### Approval date

2010-01-05, 1388/10/15

#### Ethics committee reference number

36491/5

## Health conditions studied

### 1

#### Description of health condition studied

Bone pains in Cancer patients with bone metastases

#### ICD-10 code

C79.5

#### ICD-10 code description

Secondary malignant neoplasm of bone and bone marrow

### 2

#### Description of health condition studied

Hypercalcemia in Cancer patients with bone metastases

#### ICD-10 code

E83.5

#### ICD-10 code description

Disorders of calcium metabolism

### 3

#### Description of health condition studied

Quality of life in Cancer patients with bone metastases

#### ICD-10 code

Y98

#### ICD-10 code description

Lifestyle-related condition

## Primary outcomes

### 1

#### Description

Bone pains

#### Timepoint

Before intervention - 3 months after intervention

#### Method of measurement

Visual Analogue Scale

## Secondary outcomes

### 1

#### Description

Taking Sedatives

#### Timepoint

Before intervention - 3 months after intervention

#### Method of measurement

Questionnaire including Clinical data

### 2

#### Description

Taking Opiums

#### Timepoint

Before intervention - 3 months after intervention

#### Method of measurement

Questionnaire including Clinical data

## Intervention groups

### 1

#### Description

In this study, Pamidronic Acid Ampule (90 mg) with Pamidronate brand name (Made in Hospira company) was intravenously injected for 3 months (one per month) along with 500 mL of Normal Saline during 2-4 hours. Data gathered through Clinical data Questionnaire and Visual Analog Scale (VAS) were compared before and after intervention.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Imam Sajad Hospital of Ramsar

##### Full name of responsible person

Dr Shahrbanoo Keyhanian

##### Street address

Imam Sajad Hospital of Ramsar, Motahari St., Ramsar, Mazandaran, Iran

##### City

Ramsar

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Vice chancellor for research of Tonekabon Islamic Azad University

**Full name of responsible person**

Dr Hossein Ali Mashayekhi

**Street address**

Vice chancellor for research, Tonekabon Islamic Azad University

**City**

Tonekabon

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice chancellor for research of Tonekabon Islamic Azad University

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Vice chancellor for research of Tonekabon Islamic Azad University

**Full name of responsible person**

Dr Hossein Ali Mashayekhi

**Position**

Vice chancellor for research/PhD of Chemistry

**Other areas of specialty/work****Street address**

Vice chancellor for research, Tonekabon Islamic Azad University, Tonekabon, Mazandaran, Iran

**City**

Tonekabon

**Postal code****Phone**

+98 19 2427 1105

**Fax****Email**

moaven.rsch.@tonekaboniau.ac.ir

**Web page address**

## Person responsible for scientific

## inquiries

**Contact****Name of organization / entity**

Tonekabon Islamic Azad University

**Full name of responsible person**

Dr Hossein Ali Mashayekhi

**Position**

PHD of Chemistry

**Other areas of specialty/work****Street address**

Vice chancellor for research, Tonekabon Islamic Azad University, Tonekabon, Mazandaran, Iran

**City**

Tonekabon

**Postal code****Phone**

+98 19 2427 1105

**Fax****Email**

moaven.rsch.@tonekaboniau.ac.ir

**Web page address**

## Person responsible for updating data

**Contact****Name of organization / entity**

Obstetrics Department, Tonekabon Islamic Azad University

**Full name of responsible person**

Maryam Zakerihamidi

**Position**

Faculty member of Tonekabon Islamic Azad University/PhD student of Reproductive Health

**Other areas of specialty/work****Street address**

Obstetrics Department, Islamic Azad University, Tonekabon, Mazandaran, Iran

**City**

Tonekabon

**Postal code****Phone**

00

**Fax****Email**

maryamzakerihamidi@yahoo.co.nz

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

